While Oracle’s operational performance remains strong—supported by steady cloud infrastructure growth, expanding AI-related workloads, and resilient recurring revenue—the current stock price embeds ...
Oracle faces Q2 earnings with heightened investor focus on debt plans, cash flow trajectory, and progress on its $300B OpenAI deal. Despite strong RPO and cloud growth, ORCL's valuation offers limited ...
Collecting llm-ollama Using cached llm_ollama-0.7.1-py3-none-any.whl.metadata (5.2 kB) Requirement already satisfied: llm in /opt/homebrew/Cellar/llm/0.19.1/libexec ...
The FDA has approved Astellas’s zolbetuximab (Vyloy) for HER2-negative, claudin-18.2 (CLDN18.2)-positive gastric or gastroesophageal junction (GEJ) adenocarcinomas. It is the first CLDN18.2-targeted ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback